Given that AXL plays a crucial role in cancer progression and therapeutic resistance, combining AXL inhibitors with other receptor tyrosine kinase inhibitors offers a promising strategy for overcoming acquired resistance and enhancing drug sensitivity. Here, NTRK1 is linked to cancer.